Actio locks in $55M Series A raise to advance rare disease pipeline based on human genetic platform

Reynald Castañeda

Deputy Editor

Actio Biosciences has secured a Series A raise worth $55 million to advance its clinical pipeline in rare diseases, particularly in patients with ion channel …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Actio locks in $55M Series A raise to advance rare disease pipeline based on human genetic platform

Reynald Castañeda

Deputy Editor

Sign up to read this article for free.

First meeting of CDC vaccine advisors in the Kennedy era is postponed

In single case, spinal muscular atrophy drug given before birth spared baby of genetic disease symptoms

How Keymed steered the China-to-US NewCo model in biotech

BridgeBio’s heart disease drug Attruby sails past prescription estimates

Drug packaging manufacturers brace for impact as EU chemical ban looms

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Ac­tio locks in $55M Se­ries A raise to ad­vance rare dis­ease pipeline based on hu­man ge­net­ic plat­form

Reynald Castañeda

Deputy Editor

Sign up to read this article for free.

First meet­ing of CDC vac­cine ad­vi­sors in the Kennedy era is post­poned

In sin­gle case, spinal mus­cu­lar at­ro­phy drug giv­en be­fore birth spared ba­by of ge­net­ic dis­ease symp­toms

How Keymed steered the Chi­na-to-US New­Co mod­el in biotech

Bridge­Bio’s heart dis­ease drug At­tru­by sails past pre­scrip­tion es­ti­mates

Drug pack­ag­ing man­u­fac­tur­ers brace for im­pact as EU chem­i­cal ban looms

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

Actio locks in $55M Series A raise to advance rare disease pipeline based on human genetic platform

First meeting of CDC vaccine advisors in the Kennedy era is postponed

In single case, spinal muscular atrophy drug given before birth spared baby of genetic disease symptoms

How Keymed steered the China-to-US NewCo model in biotech

BridgeBio’s heart disease drug Attruby sails past prescription estimates

Drug packaging manufacturers brace for impact as EU chemical ban looms

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence